Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus placebo after resection for esophageal or gastroesophageal junction cancer
NL-OMON59570Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer and esophagogastric junction cancer comparing Nivolumab with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON59570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59570.